Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 17,52 € ( 101,38 %). Der Median liegt bei 15,67 € ( 80,11 %).
Kaufen |
3 |
Halten |
0
|
Verkaufen |
0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 6 / 18 |
Levermann-Strategie | -3 / 13 |
Beliebteste Broker
News
- 25.10. - 20:30 Uhr
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 25, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On October 23, 2024, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities or voting rights. » Mehr auf globenewswire.com
- 22.10. - 20:30 Uhr
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET. » Mehr auf globenewswire.com
- 15.10. - 20:30 Uhr
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 15, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received three transparency notifications as detailed below. Jürgen Hambrecht On October 15, 2024, Nyxoah received a transparency notification from Jürgen Hambrecht and Jürgen Hambrecht's controlled undertaking JH Capital GmbH following an acquisition or disposal of voting securities or voting rights. » Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 771,00k | 30,35% |
Bruttoeinkommen | 170,00k | 124,71% |
Nettoeinkommen | 13,12 Mio | 2,56% |
EBITDA | 12,71 Mio | 15,52% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 299,67 Mio € |
Anzahl Aktien | 34,36 Mio |
52 Wochen-Hoch/Tief | 18,44 € - 3,69 € |
Dividenden | Nein |
Beta | 0,6 |
KGV (PE Ratio) | 6,18 |
KGWV (PEG Ratio) | 4,69 |
KBV (PB Ratio) | 2,24 |
KUV (PS Ratio) | 62,72 |
Unternehmensprofil
Nyxoah S.A., ein Medizintechnikunternehmen, konzentriert sich auf die Entwicklung und Vermarktung von Lösungen zur Behandlung von schlafbezogenen Atmungsstörungen. Es bietet das Genio-System an, eine CE-gekennzeichnete, patientenzentrierte und hypoglossale Neurostimulationstherapie zur Behandlung mittelschwerer bis schwerer obstruktiver Schlafapnoe. Das Unternehmen wurde 2009 gegründet und hat seinen Hauptsitz in Mont-Saint-Guibert, Belgien.
Name | NYXOAH S.A. |
CEO | Olivier Taelman |
Sitz | Mont-Saint-Guibert,
Belgien |
Website | |
Industrie | Gebrauchsgüter |
Börsengang | 28.04.2021 |
Mitarbeiter | 146 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | NYXH |
Brussels Stock Exchange | NYXH.BR |
Frankfurt | 5YI.F |
Düsseldorf | 5YI.DU |
München | 5YI.MU |
Assets entdecken
Shareholder von NYXOAH S.A. investieren auch in folgende Assets